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use#LAARecombinant human factor VIIa (rFVIIa) is often used 
oﬀ  -label in massively bleeding patients. A recent review 
of use in the USA [1] and a meta-analysis of studies for 
nonapproved indications [2] document the frequent use 
of rFVIIa in a variety of clinical conditions charac  terized 
by a real risk of death or major morbidity from 
exsanguination.
Th   e literature demonstrates an association between use 
of rFVIIa and increased risk of arterial thromboembolic 
complications [3]. Th  is increased risk is, of course, a 
predictable side eﬀ  ect of a procoagulant drug, and can 
actually be regarded as proof of its physiologic eﬀ  ect. 
Th  ese recent studies have raised doubts about the 
advisability of giving this product to massively bleeding 
patients, and have prompted some hospitals to ban or 
restrict the use of the drug in hemorrhaging patients. Yet 
the eﬃ   cacy of rFVIIa as a hemostatic agent is actually 
well established. Perhaps the numerous case reports on 
the cessation of bleeding will not be entirely convincing 
to all defenders of evidence-based medicine, but the 
results from prospective randomized, placebo-controlled 
trials should be.
Two double-blinded randomized, placebo-controlled 
trials have convincingly demonstrated that adminis  tra-
tion of rFVIIa in massive bleeding can reduce the need 
for blood transfusions [4,5]. In the ﬁ  rst trial, red blood 
cell transfusion was signiﬁ  cantly reduced in patients with 
blunt trauma. Moreover, just 14% of rFVIIa-treated blunt 
trauma patients received massive transfusions compared 
with 33% of placebo-treated patients (P = 0.03); in pene-
trat  ing trauma, 19% of the placebo-treated patients 
received massive transfusions compared with only 7% of 
the treated group (P = 0.08). In the second trial, which 
was conducted to examine the 30-day mortality of 
patients receiving rFVIIa, the number of units of red 
blood cells administered to blunt trauma patients (the 
majority of patients studied) was signiﬁ   cantly less in 
rFVIIa-treated patients than in placebo-treated patients 
(6.9 vs. 8.9 units, P = 0.04). Th  e same was true for the 
number of units of fresh frozen plasma administered (4.7 
vs. 6.9, P <0.01).
Despite decreasing blood use, this latter study was not 
able to demonstrate a signiﬁ  cant reduction in mortality – 
the primary endpoint – with rFVIIa use because the 
overall mortality in this entire cohort of severely injured 
patients was only 11%, and the trial had been powered 
based on the observed historical mortality of 25 to 30% in 
similarly injured patients [5]. Th  is pivotal trial was 
therefore stopped early, for scientiﬁ  c futility. Th  e  authors 
attributed the overall decrease in mortality of the entire 
cohort to advancing global standards in trauma care and 
to the meticulous application of evidence-based 
principles for resuscitation, transfusion and critical care 
management to all patients.
In these circumstances, especially bearing in mind the 
heterogeneity of trauma patients, it is virtually impossible 
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Trauma is a major cause of death worldwide, with 
some 30% of deaths associated with hemorrhage. 
Rapid control of bleeding in such patients is thus an 
essential aspect of trauma care. Recombinant human 
factor VIIa is sometimes used off  -label in massively 
bleeding patients and has been demonstrated in two 
randomized trials to signifi  cantly reduce the need 
for blood transfusions. Whether this translates into 
improved outcomes has not been determined, most 
notably because mortality appears to be much lower 
than in the past as a result of improved general care of 
trauma patients. In this setting it may be increasingly 
diffi   cult to demonstrate that any intervention can 
infl  uence survival since the number of patients needed 
for suffi   cient power is so high and the duration needed 
for recruitment of the patients too long. In the present 
commentary, we refl  ect on how we can move forward 
in the management of severely bleeding trauma 
patients in the current environment.
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patients that would be required becomes prohibitive, as 
does the amount of time that would be needed to 
perform such a study: 573 patients were recruited over 
3 years in the CONTROL study [5]. During prolonged 
study periods like this, important practices may change, 
inﬂ  uencing outcomes. Similarly, global improvements in 
the management of acute respiratory failure and decreases 
in permanent renal failure have made the observation of 
changes in major morbidities in these populations 
diﬃ   cult.
Th  ese observations raise two important issues. First, 
will it be possible to conduct trials in massively bleeding 
patients or in polytrauma victims? If we cannot demon-
strate a reduction in mortality or morbidity rates, what 
should be the endpoints of further studies? What kinds of 
studies should we propose in order to deﬁ  ne the place of 
rFVIIa or the newer procoagulants that are now emerg-
ing? Second, what can we reasonably do the next time we 
are about to lose a young trauma victim to exsanguina-
tion? Should we give rFVIIa and risk being accused of 
oﬀ  -label use of a drug without an accepted beneﬁ  t–risk 
proﬁ  le, or should we deny the patient the beneﬁ  t of a 
potentially life-saving product that clearly reduces 
bleeding?
What the clinician needs is an understanding of risks 
and beneﬁ  ts that can be artfully applied to the care of 
individual patients. Clearly, almost any therapy is justiﬁ  ed 
at some level of risk of patient death, no matter how 
unlikely it is to succeed. But how should this risk be 
assessed? How should imminent death be weighed 
against the risk of future complications, especially if they 
can be prevented or treated in a surviving patient?
Experienced high-volume trauma centers, including 
British and American military hospitals in Iraq and 
Afghani  stan, have seen their use of rFVIIa fall in recent 
years (see Figure 1 in [1]). Th   is fall in use is thought to be 
the result of an improved understanding of damage 
control resuscitation, and of a natural centering of the 
pendulum of enthusiasm for rFVIIa. But use has not 
fallen to zero. Th  ere remain situations – at least in the 
practice of the most experienced trauma clinicians – 
when use of rFVIIa is both appropriate and life-saving. 
As with other interventions in intensive care, it is likely 
that the greatest eﬀ  ect of rFVIIa will come if it is used 
early, and late administration is more likely to be futile. 
Better methods of identifying early those patients who 
are most likely to beneﬁ  t are needed to help guide the 
appropriate use of rFVIIa. Importantly, too, in contrast to 
prospective, randomized trials in older populations [3], 
studies of rFVIIa in trauma have not demonstrated an 
increased risk of thromboembolic complications above 
the baseline [4,6]. Th  e risk of arterial thrombosis is 
probably related to the presence of occult endothelial 
disruption from speciﬁ   c injuries, making individual 
clinical assessment even more important.
Reactive restrictions to oﬀ   -label use of rFVIIa may 
represent the loss of both the baby and the bathwater. We 
prefer to advocate respect for the judgment of clinicians 
who must make hard choices in the management of high-
risk patients, and call for continued research to support 
their true need – a better understanding of which 
patients will beneﬁ  t from procoagulant therapies, and of 
the real incidence and severity of risks.
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